Business
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference\n\n\n\n\n\nAmarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference\nPR Newswire\nSAN FRANCISCO, February 9, 2016\n\n\n\nSAN FRANCISCO, February 9, 2016 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it will be a featured presenting company at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference which takes place on February 10-11, 2016 in New York City. The Company's presentation will be given on Wednesday, February 10, 2016 at 12:30 pm by Gerald E. Commissiong, President & CEO of Amarantus, in the OneMedMarket Venture Track. The presentation will provide an update on the Company's regulatory interactions with FDA. Amarantus' CEO will be available for one-on-one meetings at the conference.\n\nAbout Amarantus BioScience Holdings, Inc. \n\nAmarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. More recently, AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Pr...